Sumitomo Pharma Management
Management criteria checks 2/4
Sumitomo Pharma's CEO is Toru Kimura, appointed in Jan 2016, has a tenure of 8.58 years. directly owns 0.02% of the company’s shares, worth ¥43.91M. The average tenure of the management team and the board of directors is 2 years and 3.6 years respectively.
Key information
Toru Kimura
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 9yrs |
CEO ownership | 0.02% |
Management average tenure | 2yrs |
Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?
Nov 25Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?
Sep 12There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise
Aug 16A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb
Jun 26Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?
May 13Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues
Apr 17CEO
Toru Kimura (64 yo)
9yrs
Tenure
Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Representative Director | 9yrs | no data | 0.020% ¥ 43.9m | |
Rep. Dir. and EVP of Corp. Plan. | less than a year | no data | no data | |
Executive Officer of Legal & Compliance; Intellectual Property & Human Resources | less than a year | no data | no data | |
E.O. of Corp. Reg. Comp. & Q.A. | 2yrs | no data | no data | |
Managing Executive Office | 7.8yrs | no data | 0.0020% ¥ 4.5m | |
Exec. Off. | 2yrs | no data | no data | |
Executive Officer | 2yrs | no data | no data | |
Mng. Exe. Off. of Supply Chain Div. | 3.8yrs | no data | no data | |
Executive Officer | 2yrs | no data | 0.00076% ¥ 1.7m | |
Managing Executive Officer of Research & Dev.Div. and SVP & Head of Drug Deve. Div. | 2yrs | no data | no data | |
Executive Officer | no data | no data | no data | |
Exec. Off. of Sales & Mark. Div. | less than a year | no data | no data |
2.0yrs
Average Tenure
63yo
Average Age
Experienced Management: 4506's management team is considered experienced (2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Representative Director | 8.6yrs | no data | 0.020% ¥ 43.9m | |
Rep. Dir. and EVP of Corp. Plan. | less than a year | no data | no data | |
Executive Officer | less than a year | no data | 0.00076% ¥ 1.7m | |
Independent Outside Director | 6.6yrs | no data | no data | |
Independent Outside Director | 3.6yrs | no data | no data | |
Independent Outside Director | 5.6yrs | no data | no data | |
Director | less than a year | no data | no data | |
Full-Time Audit & Supervisory Board Member | 6.6yrs | no data | 0.0065% ¥ 14.6m | |
Outside Audit & Supervisory Board Member | 6.6yrs | no data | no data | |
Full-Time Audit & Supervisory Board Member | 1.6yrs | no data | 0.0035% ¥ 7.9m | |
Outside Audit & Supervisory Board Member | 3.6yrs | no data | no data | |
Independent Outside Director | 2.6yrs | no data | no data |
3.6yrs
Average Tenure
66yo
Average Age
Experienced Board: 4506's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/03 01:34 |
End of Day Share Price | 2024/12/30 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sumitomo Pharma Co., Ltd. is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Atsushi Seki | Barclays |
Ritsuo Watanabe | BofA Global Research |
Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |